Netherlands Diabetes Device Market Analysis
The Netherlands Diabetes Device Market is expected to grow significantly, reaching US$ 343.4 million in 2023 and projected to expand to US$ 641.7 million by 2032, growing at a CAGR of 7.20% from 2024 to 2032. This growth is fueled by a combination of factors, including an aging population, increasing diabetes prevalence, the rise of remote monitoring solutions, and continuous technological advancements in diabetes care.
Request a free sample copy of the report: https://www.renub.com/netherlands-diabetes-market-p.php
Overview of the Netherlands Diabetes Device Market
Diabetes has become a major health concern in the Netherlands, with approximately 1.1 million people (around 6.4% of the adult population) affected by the condition in 2021. Of these, 90% suffer from Type 2 diabetes, which is primarily associated with lifestyle factors and aging. Annually, around 58,000 new cases of diabetes are diagnosed, and the disease remains one of the leading causes of morbidity and mortality in the country.
In response to the growing prevalence of diabetes, the market for diabetes devices in the Netherlands has experienced significant development. Diabetes devices, including continuous glucose monitors (CGMs), insulin pumps, and blood glucose meters, are essential tools in managing blood sugar levels. These devices help patients maintain a healthier lifestyle by providing accurate readings and enabling real-time adjustments to treatment plans.
Key diabetes devices in use in the Netherlands include:
- Blood glucose meters: Portable devices that allow patients to monitor their blood sugar levels at home, ensuring timely interventions in their management plan.
- Insulin pumps: These devices deliver insulin through a small tube inserted under the skin, offering a more flexible and precise way to manage insulin delivery than traditional injections.
- Continuous glucose monitors (CGMs): Devices that provide real-time blood sugar data, allowing for better decision-making and reducing the risk of complications.
Growth Drivers for the Netherlands Diabetes Device Market
- Aging Population and Rising Diabetes Prevalence
The increasing prevalence of Type 2 diabetes in the Netherlands is largely due to the aging population, which is a significant driver of demand for diabetes management devices. As people age, they become more susceptible to diabetes due to factors like decreased insulin sensitivity, increased body weight, and sedentary lifestyles. This demographic shift requires more efficient tools for monitoring and managing the condition.
Older adults are particularly prone to complications like kidney disease, blindness, and amputations, which makes effective diabetes management crucial. The growing demand for insulin pumps, CGMs, and remote monitoring systems is a direct result of this demographic trend. These devices help older patients maintain more consistent blood sugar levels, reducing the risk of severe complications and improving their quality of life.
- Technological Advancements in Diabetes Devices
Technological innovation is playing a key role in shaping the future of diabetes management in the Netherlands. Advancements in continuous glucose monitoring (CGM) systems, insulin pumps, and remote monitoring tools have significantly improved patient outcomes. These devices offer more accurate, real-time data, enabling patients to make proactive decisions about their insulin therapy, diet, and lifestyle.
CGMs, for instance, provide continuous, real-time blood glucose readings, giving patients more detailed insights into their condition. This technology enables personalized care by alerting patients to blood sugar fluctuations, allowing them to make timely adjustments to their treatment plans.
Additionally, insulin pumps offer greater flexibility compared to traditional insulin injections, allowing for more precise insulin delivery and reducing the inconvenience and discomfort of multiple daily injections.
- Increasing Demand for Remote Monitoring Solutions
There is a growing demand for remote monitoring solutions in the Netherlands, driven by the increasing popularity of telehealth services. Remote monitoring allows for continuous tracking of blood glucose levels and other health metrics without the need for frequent in-person visits. This shift toward virtual healthcare has been accelerated by the COVID-19 pandemic, which highlighted the need for alternative ways of managing chronic conditions like diabetes.
CGMs and mobile health applications are at the forefront of this trend, allowing patients to monitor their condition in real-time and share data with healthcare providers. Remote monitoring systems provide more personalized and efficient care, allowing for timely interventions by healthcare professionals, especially for those managing long-term diseases like diabetes.
This shift is empowering patients to take control of their health, reduce the number of hospital visits, and manage their condition proactively. As remote monitoring technologies become more widespread, the adoption of diabetes management devices is expected to increase significantly in the coming years.
Netherlands Diabetes Device Market: Company Analysis
Several key players dominate the Netherlands Diabetes Device Market, offering a range of products to meet the growing demand for diabetes management solutions. These companies are at the forefront of innovation, constantly improving their devices to meet patient needs.
- Dexcom Inc.
Dexcom is a leader in the continuous glucose monitoring (CGM) space. Their real-time CGM systems are widely used by patients in the Netherlands, providing accurate, continuous blood glucose readings. In February 2024, Dexcom launched its Dexcom ONE+ CGM system in Europe. This customizable device can be worn at three different body locations, offering users greater flexibility and convenience in diabetes management.
- Medtronic
Medtronic is another major player in the Dutch diabetes device market. The company is known for its insulin pumps and continuous glucose monitoring systems, which help patients manage their blood glucose levels more effectively. Medtronic’s MiniMed™ 780G insulin pump system is one of the most advanced devices on the market, offering automated insulin delivery and real-time glucose monitoring.
- Roche
Roche is a key player in diabetes care, offering a range of products, including blood glucose meters and continuous glucose monitors. In 2023, Roche launched the Accu-Chek® Guide System in the Netherlands, which is designed to make it easier for patients to measure their blood glucose levels accurately. The system offers a range of features, including a simple, user-friendly interface and advanced error detection to ensure accurate readings.
- Abbott Laboratories
Abbott is known for its Freestyle Libre system, a widely used continuous glucose monitoring system that has gained popularity for its convenience and accuracy. The Freestyle Libre provides continuous monitoring without the need for fingerstick testing, making it a preferred choice for many people living with diabetes.
- Eli Lilly
Eli Lilly is a leading pharmaceutical company that also offers diabetes management devices, including insulin delivery systems. The company is investing in the development of new, more efficient insulin pumps and injectors to better serve patients in the Netherlands.
Recent Developments in the Netherlands Diabetes Device Market
- Dexcom ONE+ Launch (February 2024)
In early 2024, Dexcom Inc. launched the Dexcom ONE+ real-time CGM system in Europe. This new system is customizable and can be worn at three different body locations, allowing users greater flexibility. The device is part of Dexcom’s broader effort to expand its presence in the European market and offer more innovative diabetes management solutions.
Related Report:
Global Human Microbiome Market
Germany In-Vitro Diagnostics Market
Europe In-Vitro Diagnostics Market
- Roche’s Accu-Chek® Guide System Launch (2023)
In 2023, Roche introduced the Accu-Chek® Guide System in the Netherlands. This new system is designed to simplify blood glucose testing and improve accuracy, with a focus on patient convenience and ease of use. The launch further strengthens Roche’s position in the Dutch diabetes care market.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:[email protected]
Need A Massage? Learn How To Give One To Yourself And Your Loved Ones
Receiving a massage, whether it’s given by someone else or self-administered, can help loosen your muscles and establish a better connection not only with your body but also with the people you love.
